RECRUITING

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Talk to us

Conditions

Alzheimer's DiseaseLewy Body DementiaParkinson's Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The study is designed to characterize the clinical, neuropsychological, polysomnographic, and neuroimaging findings among subjects with Alzheimer's disease, Lewy Body dementia, and Parkinsons' Disease.

Official Title

Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease

Quick Facts

Study Start:2018-08-30
Study Completion:2024-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03019757

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Subjects must meet the standard clinical criteria of the syndromes of interest
  2. * All subjects must have enough cognitive abilities to complete study procedures, which will be operationally defined as having a Mini Mental State Examination (MMSE) score greater or equal to 10.
  3. * Subjects must be on stable cognitive and psychoactive medication regimen for the preceding four weeks of enrollment.
  4. * Subjects must have a responsible study partner that either lives with them or is in regular contact with them at least 4 out of 7 days per week.
  5. * Subjects must have visual and auditory acuity adequate for testing.
  1. * Any other condition (other than the primary diagnosis), which in the opinion of the investigators might contribute to the syndrome of dementia or complicate its assessment.
  2. * active medical disorder that could preclude participation in this protocol
  3. * Women who are pregnant or are breast feeding
  4. * severe renal impairment as defined by glomerular filtration rate (GFR) less than 30 (may have increased radiation exposure with the DaTscan).
  5. * Subjects in whom English is not the 1st language
  6. * Subjects with educational level less than 12 years
  7. * Subjects who have ever participated in an experimental study with an amyloid targeting agent unless it can be documented that the subject received only placebo during the course of the trial.

Contacts and Locations

Study Contact

Jennifer Icenhour
CONTACT
614-293-6882
jennifer.icenhour@osumc.edu

Principal Investigator

Douglas W Scharre, MD
PRINCIPAL_INVESTIGATOR
Ohio State University

Study Locations (Sites)

The Ohio State University
Columbus, Ohio, 43210
United States

Collaborators and Investigators

Sponsor: Douglas Scharre

  • Douglas W Scharre, MD, PRINCIPAL_INVESTIGATOR, Ohio State University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-08-30
Study Completion Date2024-12

Study Record Updates

Study Start Date2018-08-30
Study Completion Date2024-12

Terms related to this study

Additional Relevant MeSH Terms

  • Alzheimer's Disease
  • Lewy Body Dementia
  • Parkinson's Disease